ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms.
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.BMC cancer · 2021Article
- Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.European journal of nuclear medicine and molecular imaging · 2020Article
- Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.Current pharmaceutical design · 2020Review
- Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer.Chonnam medical journal · 2019Article
- An introduction to the clinical practice of theranostics in oncology.The British journal of radiology · 2018Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
9 authors at 1 institution in 1 country.
Mark TulchinskyMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Richard P BaumMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
K G BennetMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Leonard M FreemanMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Ian JongMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Kalevi KairemoMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Carol S MarcusMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Renee M MoadelMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Paritosh SumanMark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los Angles, Los Angeles, CA; Renee M. Moadel, Albert Einstein College of Medicine, Bronx, NY; and Paritosh Suman, Columbia University-Harlem Hospital Center, New York, NY.
Theranostics (New Zealand) · NZ
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaHematologic NeoplasmsHumansIodine RadioisotopesThyroidectomyThyroid NeoplasmsIodine Radioisotopes
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.